Login / Signup

CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER + breast cancer.

Chih-Yi LinChung-Jen YuChun-Yu LiuTa-Chung ChaoChi-Cheng HuangLing-Ming TsengJiun-I Lai
Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)
Our study suggests a novel link between CDK4/6 inhibitor and UPP pathway, adding to the potential mechanisms of their clinical efficacy in cancer.
Keyphrases
  • cell cycle
  • small molecule
  • papillary thyroid
  • estrogen receptor
  • cell proliferation
  • childhood cancer
  • breast cancer cells
  • climate change
  • young adults